Deerfield Management

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

R3 Vascular develops bioresorbable scaffold technology coated with sirolimus for treating peripheral arterial disease. Its proprietary polymer and technologies create scaffolds that balance strength and flexibility, with a thin strut thickness of 98 microns.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Presidio Medical is a clinical-stage medical device company based in South San Francisco, California. It develops a neuromodulation platform intended to treat chronic pain by modulating neural activity and addressing disorders of neuronal function. The company pursues bioelectronic medicine to create a new class of therapeutic devices, combining biotechnology and neuromodulation to provide remedies for neural disorders.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy-based treatments for severe and life-threatening rare genetic diseases. Its pipeline includes therapies for Sanfilippo syndrome types A and B, epidermolysis bullosa, Batten disease, cystic fibrosis, and genetic eye disorders.

Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, that specializes in developing and commercializing clinical solutions for neurointerventional procedures. Founded in 2013, the company offers a range of innovative products designed to enhance patient outcomes in treating ischemic strokes. Its portfolio includes high flow tubing, diagnostic and guide catheters, distal access catheters, and aspiration pumps, as well as embolic protection and clot retrieval devices. MIVI Neuroscience focuses on providing healthcare professionals with unique tools that aim to improve the safety and efficacy of interventional therapies, ultimately reducing complications and procedure times while expanding treatment options for patients.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Founded in 2016, Liquid Wire specializes in designing and manufacturing liquid metal circuits that conform naturally to flexible surfaces. Its proprietary technology uses non-toxic, printable liquid metals on plastic and textile substrates, offering best-in-class pliability for comfort and durability.

AdaptHealth is a provider of patient-centered healthcare-at-home solutions, specializing in home medical equipment (HME), medical supplies, and associated services. The company distributes a wide range of clinically driven products designed to support patients in living independently, including sleep and respiratory therapy equipment, mobility aids, wound care supplies, and nutrition services. AdaptHealth also offers vital services such as continuous glucose monitoring and insulin pumps for diabetes management, as well as oxygen and chronic therapy services. Founded in 2012 and headquartered in Phoenixville, Pennsylvania, the company serves patients and healthcare institutions across several states, including Pennsylvania, New Jersey, New York, Maryland, and Delaware. Additionally, AdaptHealth provides online bill payment services to assist patients in managing their medical equipment expenses.

Meditrina, Inc. is a medical device company based in San Jose, California, established in 2016. The company specializes in developing innovative tissue removal solutions specifically designed for intrauterine pathology. Its flagship product, the Aveta System, serves healthcare professionals by providing an all-in-one solution for hysteroscopic diagnostic and therapeutic procedures, such as the removal of polyps and fibroids. The Aveta System is notable for its compact design, which allows for seamless integration into various clinical settings, including offices and operating rooms. It features advanced capabilities such as wide-angle HD hysteroscopy, improved fluid management for better pressure control, and a small insertion diameter coupled with a large working channel, all of which contribute to optimized tissue resection and enhanced procedural efficiency.

CorVent Medical creates ventilators and respiratory products for critical care and beyond. Its RESPOND ventilator is a compact, ~7 kg device designed for rapid deployment in clinical settings and stockpiles, with a plug-and-play setup, built-in safeguards, and maintenance-free reliability. The company also provides ventilator tubing connectors and accessories. Based in New York and founded around 2020, CorVent Medical develops solutions intended for acute, sub-acute, and home use, leveraging technologies that support cost-effective, connected care for hospitals, healthcare staff, and patients. The RESPOND platform is designed and manufactured in the United States and intended to meet ICU ventilation standards (ISO 80601-2-12) and to offer extended shelf life, low total cost of ownership, and straightforward operation for rapid response to respiratory needs.

Founded in 2003, Intersect ENT is a medical device company based in Menlo Park, California. It specializes in developing innovative therapies for Ear, Nose, and Throat surgeons to enhance patient care, focusing on treatments for chronic rhinosinusitis.

Element Science is a medical device and digital health company that develops wearable technologies to address sudden cardiac death risk in high-risk cardiovascular patients. The company designs a wearable cardioverter defibrillator and a digital platform that combines patient-centric human factors, machine learning, and rigorous electromechanical medical device development standards. Its solutions support patients transitioning from hospital to home, providing continuous protection during daily activities such as showering and sleeping. Founded in 2011 and headquartered in San Francisco, Element Science aims to reduce avoidable mortality from heart disease through integrated sensing, analytics, and lifesaving therapy delivered via wearable technology.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

AdaptHealth is a provider of patient-centered healthcare-at-home solutions, specializing in home medical equipment (HME), medical supplies, and associated services. The company distributes a wide range of clinically driven products designed to support patients in living independently, including sleep and respiratory therapy equipment, mobility aids, wound care supplies, and nutrition services. AdaptHealth also offers vital services such as continuous glucose monitoring and insulin pumps for diabetes management, as well as oxygen and chronic therapy services. Founded in 2012 and headquartered in Phoenixville, Pennsylvania, the company serves patients and healthcare institutions across several states, including Pennsylvania, New Jersey, New York, Maryland, and Delaware. Additionally, AdaptHealth provides online bill payment services to assist patients in managing their medical equipment expenses.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Axon Therapies is a healthcare company focused on developing innovative solutions to address heart failure by targeting the sympathetic nervous system. The company has created the SAVM procedure, which utilizes a specialized device that allows clinicians to ablate the right greater splanchnic nerve through a minimally invasive catheter inserted via the groin. This procedure aims to reduce sympathetic nerve activity, restore balance in the circulatory system, and shift blood volume away from the heart, ultimately lowering heart pressures. By enabling rapid intervention, Axon Therapies enhances the likelihood of successful treatment outcomes for patients suffering from heart failure.

CathWorks is a medical technology company that applies computational science platforms to enhance percutaneous coronary intervention (PCI) therapy decisions. It offers CathWorks FFRangio, a non-invasive device delivering objective multi-vessel physiologic measurements to optimize and confirm intra-procedural PCI therapies.

Itamar Medical Ltd. is a medical device company based in Caesarea, Israel, specializing in the research, development, marketing, and sale of non-invasive medical devices for the cardiology market. Founded in 1997, the company utilizes its proprietary Peripheral Arterial Tone (PAT) signal technology to create devices that assess various cardiovascular and respiratory conditions. Its flagship products include the WatchPAT device, which facilitates home testing for sleep disorders such as obstructive sleep apnea, and the EndoPAT device, which is designed to diagnose endothelial dysfunction and evaluate the risk of coronary artery disease. Itamar Medical operates across multiple regions, including the United States, Europe, Canada, Japan, and the Asia Pacific. The company also collaborates with SoClean Inc. to enhance the distribution of its home sleep apnea test and digital health services through direct-to-consumer channels.

PQ Bypass is a medical device company based in Milpitas, California, focused on transforming the treatment of long-segment peripheral artery disease through minimally-invasive endovascular solutions. Founded in 2009, the company develops and manufactures devices such as the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System to treat peripheral vascular disease via percutaneous surgical bypass. The executive team at PQ Bypass includes recognized leaders from the medical device industry with extensive experience in developing innovative solutions for venture-backed startups and major corporations like Medtronic, Abbott, Johnson & Johnson, Covidien, and Stryker.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, specializing in innovative solutions for degenerative mitral valve disease (DMR). Founded in 2007, the company has developed the NeoChord Artificial Chordae Delivery System, a proprietary device that enables mitral valve repair to be performed while the heart is still beating. This minimally invasive technique involves a small incision, significantly reducing recovery time and complications compared to traditional procedures that require larger chest incisions and stopping the heart. NeoChord's system addresses severe mitral regurgitation caused by elongated or ruptured chordae tendineae, allowing surgeons to effectively manage blood flow without the need for cardiopulmonary bypass.

Allogene Therapeutics is a clinical-stage biotech company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. The company builds a pipeline of off-the-shelf donor-derived CAR-T products using gene-editing and proprietary cell-manufacturing technologies to enable broader patient eligibility and scalable production. Its programs include UCART19 for relapsed or refractory acute lymphoblastic leukemia and other allogeneic CAR-T candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is primarily generated from collaborations and licensing agreements.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada, specializing in the integration of automated pharmacy services within clinics and other healthcare settings. The company operates primarily through two segments: Retail Pharmacy Services and Pharmacy Technology. Its Retail Pharmacy Services segment generates most of its revenue by operating SpotRx, a full-service retail pharmacy that utilizes MedAvail's automated technology, primarily serving Medicare patients in the United States. The Pharmacy Technology segment focuses on the development and commercialization of the MedAvail MedCenter, an advanced robotic dispensing platform that can be sold or leased to third-party clients. Additionally, MedAvail offers telehealth solutions, enabling remote consultations with pharmacists via on-site kiosks and home delivery services.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Phoenix, LLC, established in 2005 and headquartered in Madison, Wisconsin, specializes in designing and manufacturing high-yield neutron generators and other commercial nuclear technologies. These products cater to diverse applications across industries such as aerospace, defense, medical, and semiconductor, including neutron radiography, cargo screening, medical isotope production, and nuclear fuel scanning. The company's commitment to practical nuclear technologies has also set a long-term goal of contributing to clean, fusion energy production.

MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, that specializes in developing and commercializing clinical solutions for neurointerventional procedures. Founded in 2013, the company offers a range of innovative products designed to enhance patient outcomes in treating ischemic strokes. Its portfolio includes high flow tubing, diagnostic and guide catheters, distal access catheters, and aspiration pumps, as well as embolic protection and clot retrieval devices. MIVI Neuroscience focuses on providing healthcare professionals with unique tools that aim to improve the safety and efficacy of interventional therapies, ultimately reducing complications and procedure times while expanding treatment options for patients.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Elutia is a commercial-stage regenerative medicine company dedicated to advancing surgical outcomes for patients receiving implantable medical devices. The company focuses on developing a new generation of differentiated products through its proprietary tissue processing platforms, resulting in a portfolio of advanced regenerative medical products that closely mimic natural biological materials. Elutia operates across several segments, including Device Protection, Women's Health, and Cardiovascular, with the Women's Health segment generating the majority of its revenue. Its products aim to address unmet clinical needs by promoting healthy tissue formation and reducing complications associated with medical device implants, such as scar-tissue formation and capsular contraction.

Conventus Orthopaedics offers orthopedic and sports medicine services, including surgery, reconstructive procedures, spine surgery, joint replacement, sports medicine, physical therapy, and fracture care. Founded by medical professionals in 2009, the company focuses on less invasive treatments for complex periarticular fractures. It employs advanced nitinol technology to create a platform that delivers robust fixation and reliable repairs. The practice is located in Maple Grove, Minnesota.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

Endologix, Inc. is a medical device company that specializes in developing, manufacturing, marketing, and selling innovative solutions for the treatment of abdominal aortic aneurysms (AAA) both in the United States and internationally. The company offers a range of minimally invasive endovascular aneurysm repair (EVAR) products, including the AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation abdominal stent graft system. Additionally, Endologix provides an endovascular aneurysm sealing (EVAS) system designed to seal aneurysms while maintaining blood flow to the legs. Their product offerings also include various extensions and accessories to tailor treatments to individual patient anatomies. Founded in 1992 and headquartered in Irvine, California, Endologix has a direct sales force as well as a network of third-party distributors and agents to market its products. The company was previously known as Radiance Medical Systems, Inc. until its name change in May 2002.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, specializing in innovative solutions for degenerative mitral valve disease (DMR). Founded in 2007, the company has developed the NeoChord Artificial Chordae Delivery System, a proprietary device that enables mitral valve repair to be performed while the heart is still beating. This minimally invasive technique involves a small incision, significantly reducing recovery time and complications compared to traditional procedures that require larger chest incisions and stopping the heart. NeoChord's system addresses severe mitral regurgitation caused by elongated or ruptured chordae tendineae, allowing surgeons to effectively manage blood flow without the need for cardiopulmonary bypass.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

SteadyMed Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutic product candidates. Based in San Ramon, California, with a research and development center in Rehovot, Israel, the company offers a unique delivery platform known as PatchPump, which is a customizable, pre-filled, and pre-programmed disposable device designed for large volume and viscous formulations. Among its key products is Trevyent, a single-use PatchPump pre-filled with treprostinil for the treatment of pulmonary arterial hypertension. SteadyMed also develops SMT-201 for the subcutaneous delivery of Ketorolac, a non-steroidal anti-inflammatory drug, and SMT-301 to deliver bupivacaine directly into surgical wound areas for localized pain relief. The company's innovative approach aims to enhance the delivery of injectable therapeutic drugs, addressing various medical needs such as pain management and chronic conditions.

Founded in 2005, Breathe Technologies develops innovative respiratory therapies aimed at improving patients' mobility and quality of life. The company specializes in lightweight, portable ventilator systems designed for use in hospitals and homes, targeting conditions such as interstitial lung diseases, neuromuscular disorders, and post-transplant care.

Conventus Orthopaedics offers orthopedic and sports medicine services, including surgery, reconstructive procedures, spine surgery, joint replacement, sports medicine, physical therapy, and fracture care. Founded by medical professionals in 2009, the company focuses on less invasive treatments for complex periarticular fractures. It employs advanced nitinol technology to create a platform that delivers robust fixation and reliable repairs. The practice is located in Maple Grove, Minnesota.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada, specializing in the integration of automated pharmacy services within clinics and other healthcare settings. The company operates primarily through two segments: Retail Pharmacy Services and Pharmacy Technology. Its Retail Pharmacy Services segment generates most of its revenue by operating SpotRx, a full-service retail pharmacy that utilizes MedAvail's automated technology, primarily serving Medicare patients in the United States. The Pharmacy Technology segment focuses on the development and commercialization of the MedAvail MedCenter, an advanced robotic dispensing platform that can be sold or leased to third-party clients. Additionally, MedAvail offers telehealth solutions, enabling remote consultations with pharmacists via on-site kiosks and home delivery services.

Epion Health, Inc. is a developer of a patient engagement platform that offers a range of mobile health applications and content through a cloud-based solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company enables patients to access health-related information on their smartphones or mobile devices, helping them learn about their health and prepare for medical visits. Additionally, the platform provides physicians with access to essential health information, including pre-loaded medical applications such as drug references, dosage calculators, and health assessments. By facilitating communication between patients and healthcare providers, Epion Health aims to enhance patient care and improve overall efficiency in the healthcare continuum.

OMNIlife science, Inc. specializes in the design, manufacture, and distribution of orthopedic devices, focusing on joint replacement solutions. Founded in 1999 and headquartered in East Taunton, Massachusetts, the company offers a range of products, including orthopedic implants for knees and hips, as well as advanced robotic navigation technology known as OMNINAV, which enhances the precision of total knee surgeries tailored to individual patients. The company serves a diverse international market, including regions such as South Africa, Switzerland, Turkey, and several European countries, distributing its products through various distributors. OMNIlife science operates as a subsidiary of Orthopaedic Synergy, Inc.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

IMRIS is a company that designs, manufactures, and markets image-guided therapy systems aimed at enhancing the effectiveness of medical treatments. Its primary product, the VISIUS Surgical Theatre, integrates advanced imaging technologies such as magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites. This setup allows for intra-operative imaging, providing timely information to clinicians during surgical and interventional procedures. IMRIS primarily serves hospitals that offer clinical services in the neurosurgical, interventional neurovascular, spinal, and cardiovascular fields. The company operates globally, with a presence in North America, Europe, the Middle East, and the Asia-Pacific region, focusing on improving visualization and the overall therapy delivery process.

Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in providing molecular information products for cancer diagnosis and treatment. The company utilizes advanced genomic profiling technologies to analyze tumor specimens, enabling healthcare providers to gain insights into individual patients' cancer profiles. This information assists in optimizing treatment strategies, particularly for targeted therapies and immunotherapies. Foundation Medicine’s product offerings include FoundationOne for solid tumors, FoundationOne Heme for blood-based cancers, and various diagnostic assays to support clinical decision-making in oncology. The company also maintains a knowledgebase, FoundationCORE, to disseminate scientific advancements and strengthen collaborations within the oncology community. Foundation Medicine has established strategic partnerships with major pharmaceutical companies and research organizations to enhance precision medicine initiatives and develop companion diagnostics for specific therapies. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

iCAD specializes in cancer detection and therapy solutions. It offers AI-driven software for digital breast tomosynthesis and breast density analysis, along with tools supporting disease detection and analysis.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

CardioMEMS is a medical device company specializing in wireless monitoring solutions for severe chronic cardiovascular conditions. Their proprietary technology involves miniature sensors implanted via minimally invasive procedures, transmitting vital data like cardiac output, blood pressure, and heart rate to enhance patient management, particularly for heart failure, hypertension, and aneurysms.

CardioMEMS is a medical device company specializing in wireless monitoring solutions for severe chronic cardiovascular conditions. Their proprietary technology involves miniature sensors implanted via minimally invasive procedures, transmitting vital data like cardiac output, blood pressure, and heart rate to enhance patient management, particularly for heart failure, hypertension, and aneurysms.

Insulet Corporation is a medical device company that develops, manufactures, and markets insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprises a tubeless, disposable insulin pod worn on the body for up to three days and a wireless handheld device that manages dosing, enabling automated, hands-free insulin delivery. The system is sold through independent distributors, pharmacy channels, and direct channels in the United States, Canada, Europe, and the Middle East. Insulet was founded in 2000.

ISTA Pharmaceuticals is a commercial-stage pharmaceutical company based in Irvine, California, focused on developing and marketing treatments for various eye diseases and conditions. Founded in 1992, the company specializes in remedies for ocular inflammation, glaucoma, dry eye, and allergies. Its marketed products include BROMDAY, an ophthalmic solution for postoperative inflammation and pain, BEPREVE for allergic conjunctivitis, ISTALOL for glaucoma, and VITRASE, used as a spreading agent in ocular treatments. ISTA is also engaged in developing several products, including over-the-counter artificial tears, PROLENSA for postoperative pain relief, and various nasal sprays for allergic rhinitis. The company sells its products to a broad range of customers, including drug wholesalers, retail pharmacies, hospitals, and managed healthcare providers. As of June 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.

Exelixis is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for cancer. Its primary product, cabozantinib, is marketed as Cometriq for metastatic medullary thyroid cancer and Cabometyx for kidney and liver cancers. Exelixis also offers Cotellic in collaboration with Roche for melanoma treatment.

NxStage Medical, Inc. is a medical technology company focused on developing, manufacturing, and marketing products for the treatment of end-stage renal disease and acute kidney failure. The company's primary product, the NxStage System One, is a portable hemodialysis system designed for home use, allowing patients to manage their treatment more conveniently. In addition to the System One, NxStage offers the PureFlow SL, which integrates water purification and dialysate production for home or in-center use, as well as chronic cartridges that support more flexible renal replacement therapy schedules. The company also provides a range of disposable products for in-center dialysis treatments, including blood tubing sets and needles. NxStage Medical operates dialysis centers and delivers training services, along with a telehealth platform called Nx2me Connected Health, which facilitates remote monitoring and management of home hemodialysis treatments. Founded in 1998 and based in Lawrence, Massachusetts, NxStage Medical operates as a subsidiary of Fresenius Medical Care Holdings, Inc.

Third Wave Technologies develops and markets molecular diagnostic products for DNA and RNA analysis, providing physicians and researchers with molecular solutions for disease analysis and treatment. Based in Madison, Wisconsin, the company offers products built on Invader chemistry used in women's health, infectious disease, genetics and pharmacogenetics, and oncology. Its portfolio includes in vitro diagnostic devices and analyte specific reagents that enable laboratories to perform hepatitis C genotyping, inherited disorders testing, and various mutations linked to genetic predispositions. The company also develops DNA and RNA analysis products for research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Sales are executed through a combination of direct clinical-market personnel and collaborative partnerships in the United States and Europe.

Novare Surgical Systems, Inc. develops, manufactures, and markets devices for minimally invasive surgery. It offers motion hand-held laparoscopic instruments, which includes graspers, dissectors, cautery, and needle holders. The company's products are used in acid reflux treatment, adrenal gland removal, colon resection, gastric bypass, hysterectomy, lung lobe removal, ovary removal, prostate removal, achalasia treatment, appendix removal, gall bladder removal, hernia repair, lymph node extraction, kidney removal, pelvic mass removal, and spleen removal procedures. It provides its products through its sales representatives in the United States, Austria, Belgium, Canada, Denmark, Greece, Israel, Italy, Korea, Sweden, Switzerland, and Turkey. Novare Surgical Systems, Inc. was founded in 1999 and is headquartered in Cupertino, California.

Founded in 2005, Breathe Technologies develops innovative respiratory therapies aimed at improving patients' mobility and quality of life. The company specializes in lightweight, portable ventilator systems designed for use in hospitals and homes, targeting conditions such as interstitial lung diseases, neuromuscular disorders, and post-transplant care.